FIRST AMENDMENT TO RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT between SALIX PHARMACEUTICALS, INC. and LUPIN LTD. Dated as of 31 March 2011Rifaximin Manufacturing and Supply Agreement • May 10th, 2011 • Salix Pharmaceuticals LTD • Pharmaceutical preparations
Contract Type FiledMay 10th, 2011 Company IndustryThis FIRST AMENDMENT TO RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT (this “Amendment”), dated as of 31 March 2011 (the “Amendment Effective Date”), is made by and between Salix Pharmaceuticals, Inc., a California corporation (“Salix”), and Lupin Ltd., a corporation organized under the laws of India (“Lupin”). Salix and Lupin are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. SECOND AMENDMENT TO RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT between SALIX PHARMACEUTICALS, INC. and LUPIN LTD. Dated as of 22 February 2013Rifaximin Manufacturing and Supply Agreement • May 10th, 2013 • Salix Pharmaceuticals LTD • Pharmaceutical preparations
Contract Type FiledMay 10th, 2013 Company IndustryThis SECOND AMENDMENT TO RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT (this “Amendment”), dated as of 22 February 2013 (the “Second Amendment Effective Date”), is made by and between Salix Pharmaceuticals, Inc., a California corporation (“Salix”), and Lupin Ltd., a corporation organized under the laws of India (“Lupin”). Salix and Lupin are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Portions of this exhibit marked [*] are omitted and are requested to be treated confidentially. THIRD AMENDMENT TO RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT between SALIX PHARMACEUTICALS, INC. and LUPIN LTD. Dated as of 15 May 2013Rifaximin Manufacturing and Supply Agreement • August 9th, 2013 • Salix Pharmaceuticals LTD • Pharmaceutical preparations
Contract Type FiledAugust 9th, 2013 Company IndustryThis THIRD AMENDMENT TO RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT (this “Amendment”), dated as of 15 May 2013 (the “Third Amendment Effective Date”), is made by and between Salix Pharmaceuticals, Inc., a California corporation (“Salix”), and Lupin Ltd., a corporation organized under the laws of India (“Lupin”). Salix and Lupin are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”